Neeraj Agarwal, MD, and Arnaud Méjean, MD, PhD, on Renal Cancer: Cytoreductive Nephrectomy Followed by Sunitinib in the Metastatic Setting
2019 ASCO Annual Meeting
Neeraj Agarwal, MD, of the Huntsman Cancer Institute, and Arnaud Méjean, MD, PhD, of the Hôpital Européen Georges-Pompidou, Paris Descartes University, discuss an update to the CARMENA trial with new phase III study results on the benefit of cytoreductive nephrectomy followed by sunitinib vs sunitinib alone in metastatic renal cell carcinoma (Abstract 4508).
Yeon Hee Park, MD, of the Samsung Medical Center, discusses phase II study findings that showed exemestane plus palbociclib with ovarian suppression improved progression-free survival compared with capecitabine in premenopausal estrogen receptor–positive metastatic breast cancer (Abstract 1007).
Matt D. Galsky, MD, of The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai, discusses phase II study findings that show switch maintenance with pembrolizumab significantly improves progression-free survival in the metastatic setting (Abstract 4504).
Hani M. Babiker, MD, of the The University of Arizona, discusses an emerging treatment that inhibits the mitotic spindle and disrupts tumor cell growth. The method has been approved by the FDA to treat some cancers and data show improved progression-free and overall survival (Abstracts 2055, 8551, e14658, e14668, e15653, e20069, e15766).
Don S. Dizon, MD, of the Lifespan Cancer Institute, and Richard T. Penson, MD, of Massachusetts General Hospital Cancer Center, discuss phase III study findings on the PARP inhibitor olaparib, which showed a significantly higher objective response rate vs nonplatinum chemotherapy for patients with ovarian cancer who relapsed, are platinum-sensitive, and have BRCA-mutant disease (Abstract 5506).
Manmeet S. Ahluwalia, MD, of the Taussig Center Institute, Cleveland Clinic, discusses phase II findings on the efficacy and immunogenicity of SurVaxM, a novel cancer vaccine targeting the tumor-specific antigen survivin in newly diagnosed glioblastoma (Abstract 2016).
